70 related articles for article (PubMed ID: 6644347)
1. Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients.
Silver HK; Connors JM; Karim KA; Kong S; Spinelli JJ; de Jong G; McLean DM; Salinas FA
J Biol Response Mod; 1983; 2(5):428-40. PubMed ID: 6644347
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
3. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
4. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer.
Perillo A; Pierelli L; Battaglia A; Salerno MG; Rutella S; Cortesi E; Fattorossi A; De Rosa L; Ferraù F; Lalle M; Leone G; Mancuso S; Scambia G
Bone Marrow Transplant; 2002 Nov; 30(9):571-8. PubMed ID: 12407431
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of low doses of alpha interferon in patients with breast cancer.
Laszlo J; Hood L; Cox E; Goodwin B
J Biol Response Mod; 1986 Jun; 5(3):206-10. PubMed ID: 3723137
[TBL] [Abstract][Full Text] [Related]
6. [Clinical effect of human fibroblast interferon on malignant cancer. (2) Immunological study of the patients under treatment].
Ezaki K; Okabe K; Domyo M; Abe K; Ogawa M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):238-43. PubMed ID: 7184400
[TBL] [Abstract][Full Text] [Related]
7. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
8. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
9. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant interferon-alpha on immune function in cancer patients.
Maluish AE; Leavitt R; Sherwin SA; Oldham RK; Herberman RB
J Biol Response Mod; 1983; 2(5):470-81. PubMed ID: 6358423
[TBL] [Abstract][Full Text] [Related]
11. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
[TBL] [Abstract][Full Text] [Related]
12. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
[TBL] [Abstract][Full Text] [Related]
13. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
14. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer.
Konjević G; Spuzić I
Neoplasma; 1993; 40(2):81-5. PubMed ID: 8350959
[TBL] [Abstract][Full Text] [Related]
15. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and immunological studies of human fibroblast interferon and human lymphoblastoid interferon in malignant diseases].
Ezaki K
Gan No Rinsho; 1983 May; 29(6):598-602. PubMed ID: 6308306
[No Abstract] [Full Text] [Related]
17. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
[TBL] [Abstract][Full Text] [Related]
18. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy.
Pongnikorn S; Fongmoon D; Kasinrerk W; Limtrakul PN
J Med Assoc Thai; 2003 Jan; 86(1):61-8. PubMed ID: 12678140
[TBL] [Abstract][Full Text] [Related]
19. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
[TBL] [Abstract][Full Text] [Related]
20. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]